Recordati Launches Prize for Paediatric Oncology Research
Recordati has launched the 12th Arrigo Recordati Prize with a 2026 focus on pediatric oncology, specifically sarcomas, offering a...
Lixte’s Q4 Focus: Advancing LB-100 & Oncology Growth
Lixte Biotechnology has set its fourth-quarter agenda and disclosed advanced negotiations to acquire complementary oncology assets, signaling a push...
Ligand Announcing Special Investor Day on December 9, 2025
Ligand Pharmaceuticals will host its annual Investor Day in New York on December 9, 2025, with management set to...
Iovance Reports Inducement Grants Under NASDAQ Listing Rule
Iovance Biotherapeutics has granted inducement stock options for 62,790 shares to nine new non-executive hires. The options are priced...
Xoma Royalty, Lava Therapeutics Amend Purchase Agreement
XOMA Royalty Corporation has amended its definitive agreement to acquire LAVA Therapeutics, cutting the initial cash consideration to $1.04...
Newgen Enters Art Tokenization Market with $2M Deal
NewgenIVF Group has signed an agreement to act as the worldwide agent for tokenizing the World Chinese Museum’s private...
CorMedix Surging, Raises 2025 Net Revenue Guidance
CorMedix posted preliminary third-quarter 2025 results showing more than $100 million in net revenue, at least $85 million from...
OGRD Alliance’s Surging, Successful Growth in Asia, MENA
OGRD Alliance is expanding its PLPC-DB phospholipoproteomic module and its Oncovix documentation program from Dubai into Asia and the...
Surging Ryoncil® Revenues: A Remarkable 69% Q2 Increase
Mesoblast reported a sharp step-up in commercial momentum for Ryoncil, its FDA-approved mesenchymal stromal cell therapy for pediatric steroid‑refractory...
Rani Soars With Oversubscribed $60.3M Private Placement
Rani Therapeutics has raised approximately $60.3 million in an oversubscribed private placement, selling Class A common stock and pre-funded...